12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

Kite Pharma Inc., National Institutes of Health deal

Kite exercised an option for exclusive, worldwide rights to commercialize IP from NIH related to T cell receptor ( TCR)-based therapies that target cancer/testis antigen 1B ( CTAG1B; NY-ESO-1) to treat NY-ESO-1-expressing cancers. NIH will be eligible for undisclosed clinical, regulatory...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >